Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Sarantopoulos, Stefanie  [Clear All Filters]
2014
Allen JL, Tata PV, Fore MS, Wooten J, Rudra S, Deal AM, Sharf A, Hoffert T, Roehrs PA, Shea TC, et al. Increased BCR responsiveness in B cells from patients with chronic GVHD. Blood. 2014.
2015
Shea T, Walko C, Chung Y, Ivanova A, Sheets J, Rao K, Gabriel D, Comeau T, Wood W, Coghill J, et al. Phase I/II Trial of Dose Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients. Biol Blood Marrow Transplant. 2015.
2019
Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, et al. AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR TREATMENT-REFRACTORY RELAPSING MULTIPLE SCLEROSIS: POSITION STATEMENT FROM THE AMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION. Biol Blood Marrow Transplant. 2019.
Youssef A, McManigle W, Sarantopoulos S. B Cells in Chronic Graft-versus-Host Disease. Hum Immunol. 2019.
Cardones AR, Sullivan KM, Green C, Chao NJ, Rowe-Nichols K, Bañez LL, Burton CS, Horwitz ME, Long GD, Rao CL, et al. Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease. JAMA Dermatol. 2019.
2020
Smith P, Thompson JC, Perea E, Wasserman B, Bohannon L, Racioppi A, Choi T, Gasparetto C, Horwitz ME, Long G, et al. Clinical and Neuroimaging Correlates of Post-Transplant Delirium. Biol Blood Marrow Transplant. 2020.
2021
Jia W, Poe JC, Su H, Anand S, Matsushima GK, Rathmell JC, Maillard I, Radojcic V, Imai K, Reyes NJ, et al. BAFF Promotes Heightened BCR Responsiveness and Manifestations of Chronic GVHD after Allogeneic Stem Cell Transplantation. Blood. 2021.
Pidala J, Kitko C, Lee SJ, Carpenter P, Cuvelier GDE, Holtan S, Flowers MED, Cutler C, Jagasia M, Gooley T, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplant Cell Ther. 2021.
2022
Buxbaum NProkopenko, Socié G, Hill GR, MacDonald KPa, Tkachev V, Teshima T, Lee SJ, Ritz J, Sarantopoulos S, Luznik L, et al. Chronic GvHD NIH Consensus Project Biology Task Force: Evolving path to personalized treatment of chronic GvHD. Blood Adv. 2022.
Lew MV, Ren Y, Lowder YP, Siamakpour-Reihani S, Ramalingam S, Romero KM, Thompson JC, Bohannon LM, McIntyre J, Tang H, et al. Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplant Candidates Ages 18-80 Years. Transplant Cell Ther. 2022.
Lin C, DiCioccio RA, Haykal T, McManigle WC, Li Z, Anand SM, Poe JC, Bracken SJ, Jia W, Alyea EP, et al. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease: SYK Inhibition in Chronic GVHD. Transplant Cell Ther. 2022.
2023
Hussaini SMQasim, Ren Y, Racioppi A, Lew MV, Bohannon L, Johnson E, Li Y, Thompson JC, Henshall B, Darby M, et al. Financial Toxicity and Quality of Life in Patients Undergoing Stem-Cell Transplant Evaluation: A Single-Center Analysis. JCO Oncol Pract. 2023:OP2300243.
Bracken SJ, Suthers A, DiCioccio RA, Su H, Anand S, Poe JC, Jia W, Visentin J, Basher F, Jordan CZ, et al. Heightened TLR7 Primes BCR-Activated Cells in Chronic Graft-Versus-Host Disease for Effector Functions. Blood Adv. 2023.
Im A, Pusic I, Onstad L, Kitko CL, Hamilton BK, Alousi AM, Flowers ME, Sarantopoulos S, Carpenter P, White J, et al. Patient-reported treatment response in chronic graft--host disease. Haematologica. 2023.
Poe JC, Fang J, Zhang D, Lee MR, DiCioccio RA, Su H, Qin X, Zhang JY, Visentin J, Bracken SJ, et al. Single-cell landscape analysis unravels molecular programming of the human B cell compartment in chronic GVHD. JCI Insight. 2023.
Rodríguez-Arbolí E, Lee CJ, Caballero-Velázquez T, Martínez C, García-Calderón C, Jiménez-León MReyes, Bermúdez-Rodríguez MAránzazu, López-Corral L, Triguero A, Onstad L, et al. Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials. Clin Cancer Res. 2023:OF1-OF11.